Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURAGESIC-12 vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent synthetic opioid agonist that primarily binds to mu-opioid receptors in the central nervous system, leading to analgesic effects by increasing potassium conductance and decreasing calcium influx, thereby inhibiting ascending pain pathways and altering pain perception.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Management of persistent, moderate to severe chronic pain in opioid-tolerant patients requiring around-the-clock analgesic therapy for an extended period,Management of breakthrough pain in opioid-tolerant patients
Mild to moderate pain,Fever
Transdermal patch, initially 12 mcg/h applied every 72 hours in opioid-naive patients; titrate based on response and tolerance.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Terminal elimination half-life is approximately 20–27 hours (range 13–44 hours) after transdermal patch removal; prolonged in elderly, hepatic impairment, and with continuous use due to drug accumulation in skin and adipose tissue.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Fentanyl is primarily metabolized in the liver via CYP3A4-mediated N-dealkylation to norfentanyl, an inactive metabolite. Approximately 75% of the dose is excreted in urine, mainly as metabolites, with less than 10% as unchanged drug.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Renal: approximately 75% as metabolites (primarily norfentanyl and other inactive metabolites) and <10% as unchanged fentanyl; fecal: approximately 9%; biliary: minor.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Approximately 80–85% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Approximately 6 L/kg (range 3–8 L/kg) after intravenous administration; high Vd indicates extensive tissue distribution and accumulation in fat and muscle.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Transdermal: approximately 92% relative to intravenous; absolute bioavailability is about 30–40% (due to first-pass metabolism, but transdermal bypasses hepatic first-pass, hence high relative bioavailability).
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
GFR 30-89 m L/min: start at 50% of usual initial dose; GFR <30 m L/min: avoid use or start at 50% of usual dose with cautious titration. Not recommended in dialysis patients.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Child-Pugh class A: start at 50% of usual initial dose; Child-Pugh class B: start at 25% of usual dose; Child-Pugh class C: avoid use due to extreme risk of toxicity.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
For pediatric patients aged 2-16 years currently receiving and tolerant to opioids (equivalent to at least 60 mg oral morphine/day): initial fentanyl dose (mcg/h) based on previous 24-hour opioid requirement using standard conversion; apply patch every 72 hours. For opioid-naive pediatric patients: not recommended.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Initiate at 50% of usual adult starting dose (e.g., 12 mcg/h every 72 hours) due to increased sensitivity and reduced clearance; titrate cautiously with longer intervals between dose adjustments.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
WARNING: LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; ABUSE POTENTIAL; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; NEONATAL OPIOID WITHDRAWAL SYNDROME; RISK OF MEDICATION ERRORS; and RISK OF SERIOUS HARM OR DEATH WITH CONCOMITANT USE OF CYP3A4 INHIBITORS. DURAGESIC is contraindicated in the management of acute or intermittent pain, or in opioid-non-tolerant patients. Accidental exposure to DURAGESIC may result in fatal respiratory depression.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Life-threatening respiratory depression, especially during initiation or dose escalation,Accidental exposure can be fatal,Risk of abuse, misuse, and addiction,Risks from concomitant use with benzodiazepines or other CNS depressants,Neonatal opioid withdrawal syndrome with prolonged use during pregnancy,Risks of medication errors (e.g., confusion with other fentanyl products),Serotonin syndrome with concomitant serotonergic drugs,Adrenal insufficiency,Severe hypotension,Risks in patients with head injury or increased intracranial pressure,Application site reactions and skin irritation,Wound healing complications in patients with surgical wounds
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Opioid non-tolerant patients,Management of acute or intermittent pain,Postoperative pain management,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity to fentanyl or any components of the system
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Avoid or limit grapefruit juice as it inhibits CYP3A4, increasing fentanyl levels and risk of adverse effects. No other significant food interactions. Alcohol should be avoided as it enhances central nervous system depression.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
Pregnancy category C. First trimester: Limited data; theoretical risk of neural tube defects if folate deficiency exacerbated. Second and third trimesters: Risk of neonatal withdrawal syndrome, respiratory depression, and decreased fetal growth; avoid prolonged use near term.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Fentanyl transfers into breast milk; M/P ratio approximately 0.17-0.47. Caution: risk of infant sedation and respiratory depression. Consider benefits vs risks; avoid if infant is <3 months or has respiratory compromise.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Pregnancy increases clearance of fentanyl by 35-50% in second and third trimesters; consider dose increase guided by pain response; postpartum clearance returns to prepregnancy levels within 48 h, requiring dose reduction.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
DURAGESIC-12 (fentanyl transdermal system) is indicated for opioid-tolerant patients only. Do not initiate in opioid-naive patients due to risk of fatal respiratory depression. Apply to non-irritated, non-irradiated skin on flat surface such as chest, back, flank, or upper arm. Avoid heat sources (heating pads, hot tubs, fever) which increase absorption. Monitor for constipation and respiratory depression, especially at start and dose titration. Not for acute pain or post-op use in opioid-naive patients.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Apply patch to clean, dry, non-hairy skin; do not cut or damage the patch.,Do not expose patch to direct heat (heating pads, hot tubs, electric blankets).,Keep patch away from children and pets; dispose of used patches by folding adhesive side together and flushing down toilet.,Do not drink grapefruit juice as it may increase fentanyl levels.,Do not stop using patch suddenly as withdrawal symptoms may occur.,Report severe drowsiness, confusion, difficulty breathing, or constipation.,Store at room temperature away from moisture and heat.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DURAGESIC-12 vs ACEPHEN, answered by our medical review team.
DURAGESIC-12 is a Opioid Analgesic that works by Fentanyl is a potent synthetic opioid agonist that primarily binds to mu-opioid receptors in the central nervous system, leading to analgesic effects by increasing potassium conductance and decreasing calcium influx, thereby inhibiting ascending pain pathways and altering pain perception.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DURAGESIC-12 and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DURAGESIC-12 is: Transdermal patch, initially 12 mcg/h applied every 72 hours in opioid-naive patients; titrate based on response and tolerance.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DURAGESIC-12 and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DURAGESIC-12 is classified as Category C. Pregnancy category C. First trimester: Limited data; theoretical risk of neural tube defects if folate deficiency exacerbated. Second and third trimesters: Risk of neonatal withdra. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.